Literature DB >> 15868333

[Glucocorticoid therapy in collagen diseases diseases].

L Unger1, M Kayser, M Enderlein, K Manger, H Nüsslein.   

Abstract

Glucocorticoids are irreplaceable for the treatment of connective tissue diseases due to their strong and rapid anti-inflammatory and immuno-modulatory effects. Its use and their dosage depend on the activity of the disease and organ manifestations. There is no alternative to high doses, often even as intravenous pulse therapy, in life-threatening situations with imminent organ failure. Despite an additional immuno- suppressive medication, glucocorticosteroids are mandatory for long-term treatment in most cases. In special situations like high age, gravity or comorbidities like renal failure or hepatosis, glucocorticosteroids are the option with the least possible potential for complications. In the future, new corticosteroids and steroid sparing immuno-suppressants like biologics will be able to reduce the spectrum and the severity of corticoid-induced side effects. Modern state-of-the-art therapeutic regimens for patients with connective tissue diseases should not only be able to sufficiently control the disease activity but also include the prophylaxis of associated comorbidities like arteriosclerosis, osteoporosis or infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15868333     DOI: 10.1007/s00393-005-0721-9

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  30 in total

Review 1.  Systemic lupus erythematosus: a model for atherogenesis?

Authors:  S Manzi
Journal:  Rheumatology (Oxford)       Date:  2000-04       Impact factor: 7.580

Review 2.  Interstitial lung disease in systemic lupus erythematosus.

Authors:  G S Cheema; F P Quismorio
Journal:  Curr Opin Pulm Med       Date:  2000-09       Impact factor: 3.155

3.  Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine.

Authors:  D Jardinet; C Lefèbvre; G Depresseux; M Lambert; J P Devogelaer; F A Houssiau
Journal:  Rheumatology (Oxford)       Date:  2000-04       Impact factor: 7.580

4.  Pattern of neuropsychologic dysfunction in inactive systemic lupus erythematosus.

Authors:  B I Glanz; D Slonim; M B Urowitz; D D Gladman; J Gough; A MacKinnon
Journal:  Neuropsychiatry Neuropsychol Behav Neurol       Date:  1997-10

5.  Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.

Authors:  John G Hanly; Grace McCurdy; Lisa Fougere; Jo-Anne Douglas; Kara Thompson
Journal:  J Rheumatol       Date:  2004-11       Impact factor: 4.666

6.  Mortality and causes of death in systemic lupus erythematosus.

Authors:  J Trager; M M Ward
Journal:  Curr Opin Rheumatol       Date:  2001-09       Impact factor: 5.006

7.  Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus.

Authors:  B D Pryor; S G Bologna; L E Kahl
Journal:  Arthritis Rheum       Date:  1996-09

Review 8.  Systemic lupus erythematosus trials: successes and issues.

Authors:  Ellen M Ginzler; Ioana Moldovan
Journal:  Curr Opin Rheumatol       Date:  2004-09       Impact factor: 5.006

Review 9.  The ACR nomenclature for CNS lupus revisited.

Authors:  O Nived; G Sturfelt; M H Liang; P De Pablo
Journal:  Lupus       Date:  2003       Impact factor: 2.911

10.  Lupus nephritis: current issues.

Authors:  C P Mavragani; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

View more
  1 in total

1.  A comparative effectiveness study of bone density changes in women over 40 following three bone health plans containing variations of the same novel plant-sourced calcium.

Authors:  Gilbert R Kaats; Harry G Preuss; Harry A Croft; Samuel C Keith; Patti L Keith
Journal:  Int J Med Sci       Date:  2011-03-02       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.